Literature DB >> 21416249

Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.

Hiromichi Yoshizawa1, Tetsu Akimoto, Katsuhiko Nishino, Makoto Inoue, Chiharu Ito, Shinichi Takeda, Atsushi Kotoda, Kaichiro Tamba, Wako Yumura, Shigeaki Muto, Yoshihiko Ueda, Eiji Kusano.   

Abstract

This report presents a case of nephrotic syndrome and renal failure that developed in a 53-year-old female with metastatic breast carcinoma. She was diagnosed to have osteolytic bone metastases 5 years prior to admission, and had been administered pamidronate with a total dose of approximately 6800 mg. A renal biopsy revealed tubulointerstitial damage and marked wrinkling and retraction of the glomerular basement membrane with hypertrophy and hyperplasia of the epithelial cells, compatible with the collapsing form of focal segmental glomerulosclerosis (FSGS). Despite the discontinuation of pamidronate after admission, her renal function gradually decreased. She was finally managed with continuous palliative care for advanced malignancy through a shared effort, and died 96 days after undergoing the renal biopsy. Although the clinical impact of the pamidronate-associated kidney injury on the longitudinal changes in renal function remains to be delineated, it is therefore reasonable to consider that the collapsing FSGS associated with tubulointerstitial damage may have resulted in the irreversible renal injuries that were observed in the current case. Further studies and accumulated experience with renal biopsy are required to better determine the relationship between pathological alterations and prognostic characteristics among patients with pamidronate-associated renal impairments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21416249     DOI: 10.1007/s10157-011-0425-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.617


  26 in total

1.  Nephrotic syndrome after treatment with pamidronate.

Authors:  Glen S Markowitz; Paul L Fine; Vivette D D'agati
Journal:  Am J Kidney Dis       Date:  2002-05       Impact factor: 8.860

2.  Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy.

Authors:  J Bariéty; D Nochy; C Mandet; C Jacquot; D Glotz; A Meyrier
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

3.  Nephrotic syndrome due to focal glomerulosclerosis and undifferentiated carcinoma.

Authors:  T Konoshita; M Itoh; S Hatakeyama; M Hirata; I Koni; R Miyazaki; Y Tofuku; H Mabuchi
Journal:  Clin Nephrol       Date:  2000-11       Impact factor: 0.975

Review 4.  Progression of glomerular diseases: is the podocyte the culprit?

Authors:  W Kriz; N Gretz; K V Lemley
Journal:  Kidney Int       Date:  1998-09       Impact factor: 10.612

5.  Permanent genetic tagging of podocytes: fate of injured podocytes in a mouse model of glomerular sclerosis.

Authors:  Takako Asano; Fumio Niimura; Ira Pastan; Agnes B Fogo; Iekuni Ichikawa; Taiji Matsusaka
Journal:  J Am Soc Nephrol       Date:  2005-06-29       Impact factor: 10.121

6.  Breast cancer with nephrotic syndrome: report of two cases.

Authors:  Yuko Kijima; Heiji Yoshinaka; Tetsuhiro Owaki; Tsuyoshi Nozaki; Toshio Hamada; Yuichiro Yasumoto; Takashi Aikou
Journal:  Surg Today       Date:  2004       Impact factor: 2.549

Review 7.  Bisphosphonate nephrotoxicity.

Authors:  Mark A Perazella; Glen S Markowitz
Journal:  Kidney Int       Date:  2008-08-06       Impact factor: 10.612

Review 8.  Management of the adverse effects associated with intravenous bisphosphonates.

Authors:  T Tanvetyanon; P J Stiff
Journal:  Ann Oncol       Date:  2006-03-17       Impact factor: 32.976

Review 9.  The use of bisphosphonates in cancer patients.

Authors:  Shenhong Wu; William L Dahut; James L Gulley
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

Review 10.  Pamidronate-induced nephrotoxic tubular necrosis--a case report.

Authors:  S Smetana; A Michlin; E Rosenman; A Biro; M Boaz; Z Katzir
Journal:  Clin Nephrol       Date:  2004-01       Impact factor: 0.975

View more
  1 in total

1.  Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.

Authors:  Beatrice J Edwards; Sarah Usmani; Dennis W Raisch; June M McKoy; Athena T Samaras; Steven M Belknap; Steven M Trifilio; Allison Hahr; Andrew D Bunta; Ali Abu-Alfa; Craig B Langman; Steve T Rosen; Dennis P West
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.